Historial de ingresos, beneficios y flujo de caja según los estados financieros oficiales.
Zoetis Inc. se dedica al descubrimiento, desarrollo, fabricación y comercialización de medicamentos, vacunas, productos y servicios de diagnóstico, biodispositivos, pruebas genéticas y soluciones de salud animal de precisión para la industria de la salud animal en los Estados Unidos e internacionalmente. La empresa comercializa productos principalmente para animales de compañía, incluidos perros, gatos y caballos; y especies, incluido el ganado, como bovinos, porcinos, aves de corral, peces y ovejas.
Traducido automáticamente
Ver gráficos interactivos y estados completos → Modelo de valoración (DCF) →
| Cuenta de resultados | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos totales | $9.5B | $9.5B | $9.3B | $8.5B | $8.1B | $7.8B | $6.7B | $6.3B | $5.8B | $5.3B | $4.9B | $4.8B | $4.8B | $4.6B | $4.3B | $4.2B | $3.6B | $2.8B |
| Beneficio bruto | $6.7B | $6.7B | $6.4B | $5.8B | $5.5B | $5.3B | $4.5B | $4.1B | $3.8B | $3.4B | $3.1B | $3.0B | $3.0B | $2.8B | $2.7B | $2.5B | $2.1B | $1.7B |
| % de margen bruto | 70.9% | 70.5% | 69.1% | 68.3% | 67.8% | 68.3% | 66.8% | 65.7% | 65.2% | 64.9% | 64.3% | 62.3% | 62.9% | 62.1% | 62.7% | 60.0% | 58.2% | 61.7% |
| Ingresos operativos (EBIT) | $3.5B | $3.6B | $3.4B | $3.1B | $2.9B | $2.8B | $2.3B | $2.0B | $1.9B | $1.7B | $1.4B | $1.1B | $970M | $821M | $854M | $684M | $309M | $281M |
| % de margen operativo | 37.0% | 38.0% | 36.6% | 35.9% | 36.2% | 36.0% | 34.0% | 32.2% | 32.3% | 32.5% | 28.7% | 22.7% | 20.3% | 18.0% | 19.7% | 16.2% | 8.6% | 10.2% |
| Ingresos netos | $2.6B | $2.7B | $2.5B | $2.3B | $2.1B | $2.0B | $1.6B | $1.5B | $1.4B | $864M | $821M | $339M | $583M | $504M | $436M | $245M | $110M | ($100M) |
| % de margen neto | 27.5% | 28.2% | 26.9% | 27.4% | 26.2% | 26.2% | 24.5% | 24.0% | 24.5% | 16.3% | 16.8% | 7.1% | 12.2% | 11.1% | 10.1% | 5.8% | 3.1% | -3.6% |
| EBITDA | $3.9B | $4.1B | $3.9B | $3.7B | $3.4B | $3.2B | $2.7B | $2.5B | $2.2B | $1.9B | $1.6B | $868M | $1.1B | $1.0B | $941M | $635M | $400M | $2M |
| Beneficio por acción (EPS) | $6.08 | $6.02 | $5.47 | $5.07 | $4.49 | $4.27 | $3.42 | $3.11 | $2.93 | $1.75 | $1.65 | $0.68 | $1.16 | $1.01 | $0.87 | $0.51 | $0.23 | $-0.21 |
| Acciones en circulación (M) | 418M | 444M | 455M | 462M | 470M | 477M | 479M | 482M | 487M | 493M | 498M | 502M | 502M | 500M | 500M | 482M | 482M | 482M |
Fuente: informes públicos de la empresa (SEC). Verifique en SEC EDGAR antes de confiar en cualquier cifra.
Balances, flujos de caja, datos trimestrales y ratios completos en el visor interactivo de ZTS. /companies/us/ZTS
La información de este sitio es solo educativa e informativa; no constituye asesoramiento de inversión. No se publican precios objetivo ni recomendaciones.
About TickerBase · Data methodology & sources · Privacy · Terms